Skip to main content
. 2016 Nov 3;4(4):310–319. doi: 10.14218/JCTH.2016.00027

Table 3a. Comparison of treatment guidelines for treatment-naïve patients infected with HCV genotype 3.

AASLD/IDSA EASL WHO# APASL

  • Sofosbuvir/daclatasvir (I-A)

  • Sofosbuvir/velpatasvir (I-A)a (IIa-B)

  • PegIFN-α/sofosbuvir/RBV (B1)

  • Sofosbuvir/RBV (A1)b (B1)

  • Sofosbuvir/daclatasvir (A1)c (B1)

  • Sofosbuvir/daclatasvira

  • Sofosbuvir/RBVb

Alternative

  • Sofosbuvir/PegIFN/ribavirin

  • Sofosbuvir/RBVb (A1)d (B2)

  • Sofosbuvir/daclatasvira (A2)
#

All regimens: strong recommendation, low quality of evidence.

a

± RBV for 24 weeks (cirrhotics);

b

24 weeks, option for non-cirrhotics;

c

24 weeks in patients with cirrhosis;

d

16 weeks in patients with cirrhosis.

Abbreviations: PegIFN, Pegylated interferon; RBV, Ribavirin.

All treatment courses are 12 weeks unless indicated otherwise.